The Autoimmune Drugs Market is being driven by Strong R and D pipeline
The Autoimmune Drugs Market is expected to grow at a CAGR of 6.78% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 33218.8 million.
Get more information on Autoimmune Drugs Market by requesting a sample report
The market is segmented based on
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
However, the market also witnesses some limitations, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
185 |
|
Base year |
2023 |
|
Historic period |
2017-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 6.78% |
|
Market growth 2024-2028 |
USD 33218.8 million |
|
Market structure |
fragmentation |
|
YoY growth 2023-2024(%) |
6.23 |
|
Key countries |
US, Germany, Canada, China, and UK |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Find out which segment is leading the market by accessing the free PDF report
The Autoimmune Drugs Market encompasses a range of pharmaceutical products designed to treat various autoimmune diseases, including Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, and Rheumatoid Arthritis. Key players in this market include Effector T cells and regulatory T cells, which play crucial roles in the immune response. Autoimmune drugs work by targeting specific proteins and pathways, such as Dihydroorotate dehydrogenase, Folic acid, Interferon gamma, and Biosimilars like Certolizumab pegol, Golimumab, Adalimumab, and Etanercept. Immunosuppressants, such as Cyclosporine, Antimalarials, Cyclophosphamide, Azathioprine, Sulfasalazine, Gold compounds, and NSAID therapy (including Aspirin, Willow spp, and Salicylates), are also commonly used. One emerging class of autoimmune drugs is Anti-TNF therapy, which targets the TNF protein to reduce inflammation. These drugs have been effective in treating various autoimmune diseases, including Psoriasis, Ankylosing Spondylitis, and Rheumatoid Arthritis. However, their high cost and potential side effects have led to the development of biosimilars, which offer more affordable alternatives while maintaining similar efficacy.
The global pharmaceuticals market encompasses entities involved in the research and development (R&D) or production of various offerings, including generic and non-generic drugs, as well as veterinary medicines. According to Technavio, the healthcare industry's total revenue is determined by the earnings generated by manufacturers and suppliers of medical equipment, pharmaceuticals, biotechnology, life sciences tools, and related services. Factors fueling the expansion of the pharmaceuticals sector include the increasing elderly population. By 2050, approximately one-quarter of the US population and, by 2030 in Europe, are projected to be aged 60 years or above.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
